ReviewAJR. American journal of roentgenology2017
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Review in AJR. American journal of roentgenology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 96 citations in OpenAlex.
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Framework to calculateMedical physics · 2025Article
- 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.Molecular cancer therapeutics · 2025Article
- Advancements in delivery systems for dietary polyphenols in enhancing radioprotection effects: challenges and opportunities.NPJ science of food · 2025Review
- Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations.Computational and structural biotechnology journal · 2024Article
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.Discover nano · 2024Article
- Calculation of alpha particle single-event spectra using a neural network.Frontiers in oncology · 2024Article
- Review
- Radionuclide-based theranostics - a promising strategy for lung cancer.European journal of nuclear medicine and molecular imaging · 2023Review
- Resonant laser ionization and mass separation ofScientific reports · 2023Article
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.International journal of nanomedicine · 2023Review
- Article
- Article
- SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice.Acta pharmacologica Sinica · 2022Article
- Bifunctional chelators for radiorhenium: past, present and future outlook.RSC medicinal chemistry · 2022Review
- Targeted α-therapy in non-prostate malignancies.European journal of nuclear medicine and molecular imaging · 2021Review
- Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.Journal of cellular and molecular medicine · 2021Review
Corrections and comments
- Erratum issuedCorrection.2017
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
objectiveThis article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field.
conclusionTRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.